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Abstract: The success of nanomedicine as a new strategy for drug delivery and targeting 
prompted the interest in developing approaches toward basic and clinical neuroscience. 
Despite enormous advances on brain research, central nervous system (CNS) disorders 
remain the world’s leading cause of disability, in part due to the inability of the majority  
of drugs to reach the brain parenchyma. Many attempts to use nanomedicines as CNS  
drug delivery systems (DDS) were made; among the various non-invasive approaches, 
nanoparticulate carriers and, particularly, polymeric nanoparticles (NPs) seem to be the 
most interesting strategies. In particular, the ability of poly-lactide-co-glycolide NPs (PLGA-
NPs) specifically engineered with a glycopeptide (g7), conferring to NPs’ ability to cross 
the blood brain barrier (BBB) in rodents at a concentration of up to 10% of the injected 
dose, was demonstrated in previous studies using different routes of administrations. Most 
of the evidence on NP uptake mechanisms reported in the literature about intracellular 
pathways and processes of cell entry is based on in vitro studies. Therefore, beside the 
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particular attention devoted to increasing the knowledge of the rate of in vivo BBB 
crossing of nanocarriers, the subsequent exocytosis in the brain compartments, their fate 
and trafficking in the brain surely represent major topics in this field. 
Keywords: nanomedicine; blood brain barrier; neuron; endocytosis; cellular uptake 
 
1. Introduction 
1.1. Nanomedicine and Blood Brain Barrier 
The same mechanism that protects the brain against intrusive chemicals and exogenous toxic agents 
can also frustrate therapeutic interventions. With the aim of effectively delivering a drug to the brain 
for treating specific neurological disorders (i.e., meningitis, encephalitis, degenerative diseases like 
Alzheimer’s, and Parkinson’s disease and tumors as glioblastoma), one of the first issues to be 
addressed is to overcome the blood brain barrier (BBB), which may or may not maintain its integrity 
or permeability depending on the degree of pathology. 
An ideal approach for the delivery of therapeutic agents across the BBB should be based on 
biodegradable, biocompatible carriers featuring the absence of toxicity to the barrier and producing the 
highest selectivity in therapeutic outcomes. Therefore, systemic delivery should be: (i) made of “safe” 
materials, as polymers or lipids; (ii) tailored for controlled/modified release of loaded drug; (iii) targeted 
to the BBB; (iv) to the site of target action in the brain; (v) able to allow the loaded drug to exert 
pharmacological action within the brain. To reach these goals, the transport of the drugs across the 
BBB should be appropriately planned and designed. In particular, proper evaluation of the main 
advantages of drug delivery systems in terms of ability in controlling the release of loaded drugs (i.e., 
polymer-based carriers can ameliorate drug release kinetics with respect to lipid based ones), in being 
more biocompatible and able to interact with membranes (i.e., lipid based systems can interact with a 
preferential modality or even are considered as bio-safe at a high degree) or in terms of stability in 
bloodstream (i.e., polymer-based and lipid-based should be planned to avoid elimination/metabolism 
or even de-activation by Reticulo-Endothelial System). 
To circumvent the multitude of barriers inhibiting CNS penetration by potential therapeutic agents, 
numerous drug delivery strategies (DDS) were developed [1,2]. These strategies fall into one or more 
of the following three categories: (i) chemical approach (lipophilic analogs, prodrugs); (ii) temporary 
disruption of the BBB (an invasive strategy for enhanced CNS drug delivery involving the systemic 
administration of drugs in conjunction with transient BBB disruption (BBBD)); (iii) alternative 
approaches for drug delivery as a molecular Trojan horse. 
In this view, this strategy (“Trojan horse”) has been widely applied for macromolecules themselves, 
allowing them to be selectively targeted to a desired site of action in their inactive form and, only in the 
correct place, to be activated. Thus, from the conceptual point of view, the Trojan horse approach for 
nanocarriers is quite different, as it could be referred to as the “trick” of simulating and mainly exploiting 
natural/endogenous pathways for BBB crossing by non-self, but properly engineered, nanocarriers. 
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Despite advances in rational CNS drug design and BBBD, many potentially efficacious drug 
molecules still cannot penetrate into the brain parenchyma at therapeutic concentrations. 
A winning strategy might consist in mimicking strategies used by the endothelial cells of BBB to 
exchange nutrients between CNS and blood in physiological conditions: the so called molecular Trojan 
horse. Briefly, a specific ligand can be bound onto the nanocarrier surface in order to enhance the CNS 
delivery [3–10]. 
In this paper, we analyze the case of a specific peptidic ligand (glycosylated hepta-peptide, called 
g7), which was demonstrated to be able to drive polymeric nanoparticles across the Blood Brain 
Barrier in vivo and with ability of interacting with neuronal cells (neurons mainly) with proper 
evaluations in vitro on cell cultures. 
We think that this example, referring to one single kind of NPs which were analyzed from several 
points of view, and by several independent experiments, could be useful to plan future protocols and 
approaches for evaluation of the potentiality, the role and the fate of nanocarriers aimed to target the 
Central Nervous System. 
1.2. Endocytosis of Nanomedicine 
Two main transport routes have been exploited to actively target and trigger BBB crossing: carrier-
mediated transport (CMT) and receptor-mediated endocytosis (RME). 
CMT is a form of active or passive diffusion, depending on the context, and accounts for the 
unidirectional transport of molecules from the blood to the brain. The transporters are responsible for 
the brain delivery of substrates such as D-glucose (GLUT1 glucose transporter), large neutral amino 
acids (the LAT1 large neutral amino acid transporter, the CAT1 cationic amino acid transporter), 
carboxylic acids (the MCT1 monocarboxylic acid transporter) and nucleosides (the CNT2 nucleoside 
transporter) into the brain. CMT can be used for active targeting of CNS. From a general point of view, 
nutrients or their analogues, for which specific transporters exist on BBB endothelium, can be bound to 
the nanovector surface. By this strategy, the ligand transport into the CNS lumen leads also to the 
transport of the nanocarrier bearing the ligand on its surface. Into the brain tissue, the nanovectors can 
release their cargo by different mechanisms depending on the type of carrier used. 
It should be clarified that the mechanism of BBB crossing needs to be completed in all the phases, 
meaning that the nanocarrier should be efficiently endocytosed, then submitted to transcytosis and 
require to be submitted to exocytosis. In some papers [11], it was demonstrated that if the linkage 
between the ligand and the receptors (i.e., transferrin receptor) which trigger the BBB crossing is too 
heavy, the exocytosis process does not take place. This would mean that the nanocarrier will never be 
able to interact with brain cells, since it is still linked to the endothelial cell. This event is particularly 
evident in the case of the main receptors able to trigger BBB crossing, such as transferrin and insulin, 
and therefore, the use of some antibodies with a high degree of affinity to these receptors or even the 
natural substrates of the receptors were not completely successful. 
RME or clathrin-dependent endocytosis is a highly specific and energy mediated transport enabling 
eukaryotic cells to selectively uptake macromolecules as specific cargo. The BBB receptor-specific 
ligands have also been shown to be very effective in transporting endogenous peptides like insulin, 
insulin like growth factor-I, insulin like growth factor-II, transferrin, albumin, and opioid peptides, 
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e.g., deltorphins, (D-penicillamine 2,5) enkephalin and deltorphin II [12–15]. That is why receptor-
mediated drug delivery is also a promising approach for the release of therapeutic agents into neuronal 
cells, and tissues; nanocarriers conjugated to different types of ligands for cell surface receptors 
expressed on brain endothelial cells can accumulate and eventually be internalized by cells on the 
vascular side of the brain through the mechanism of RME. Several receptors were investigated, such as 
transferrin (Tnf), insulin, thiamine, apolipoprotein receptors, beyond some peptides. OX-26 and 
8D3mAb (respectively, monoclonal antibody to rat and mouse transferrin receptor) conjugated 
nanocarriers were proven to deliver drug molecules or exogenous genes to the brain [16–19].  
83-14mAb, a murine monoclonal antibody to the human insulin receptor, coupled liposomes have 
successfully delivered mRNA, siRNA or plasmids into the rat brain [20–22]. Apolipoproteins B and E 
were also suggested to be mainly involved in the transport of polysorbate 80 coated nanoparticle-
bound drugs into the CNS: absorption of apolipoproteins from the blood after injection of surfactant-
coated nanoparticles is likely to mimic lipoprotein particles that could be taken up by the brain capillary 
endothelial cells via RME [23]. 
Another category of approaches for BBB crossing is based on peptides able to trigger BBB crossing 
by mediating endocytosis of peptides into the CNS. In particular, some categories of opioid peptides 
have been shown to penetrate the BBB and this crossing is improved when peptides are glycosylated 
as described for enkephalin analogs, vasopressin analog, deltorphin and dermorphin glycopeptide 
analog and other peptides [24,25]. Hence, in this paper, we described the use of a specific class of 
peptides, able to cross the BBB and therefore suitable for being ligands for the planning and creation 
of delivery systems for the CNS [26]. The synthetic opioid peptide MMP-2200 (H2N-L-Tyr-D-Thr-
Gly-L-Phe-Leu-L-Ser-O-beta-D-lactose-CONH2) was considered the lead [27]. The Tyr present at the 
N-terminus of MMP-2200 was substituted with the Phe in order to avoid a potential opioid effect. This 
glycopeptide was conjugated with PLGA to prepare modified polymers able to form NPs able to cross 
BBB [28]. While un-modified PLGA NPs were not able to cross BBB, peptide-conjugated NPs (g7-NPs) 
were able to cross the BBB by a systemic route g7-NPs are able to bypass the hepatic uptake, and to 
reach the brain [26,29]. Studies were also performed to assess the ability of these g7-NPs to act as drug 
carriers [30]. Loperamide, an opioid drug not able to cross the BBB, was loaded into the NPs and 
administered through systemic administration in rats; the evidence of loperamide delivery into the 
brain was achieved by the hot plate test (nociception assay). Loperamide-loaded NPs (2.7 or 1.8 mg/kg) 
produced a high antinociceptive activity 240 min after their administration. The ability of g7-NPs in 
BBB crossing was also confirmed by in vivo evidence, in rodents and after different routes of 
administration (i.p., i.v., nasal, oral) [31]. In particular, evidence of BBB crossing pathways was 
obtained after systemic administration of g7-NPs in rodents, indicating that g7-peptide, due to its 
peculiar amphipathic character, was able to selectively promote endocytosis at BBB level and 
therefore mediate BBB translocation of g7-NPs to the CNS parenchyma [32]. 
1.3. Endocytosis Mechanism and Fate of NPs 
Once the nanocarriers have crossed the BBB, a big issue is to understand their trafficking, their 
endocytosis at a single cell level and their preferential tropism. 
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In this view, a plethora of papers were published regarding the endocytosis of nanomedicine. As 
reported in a very complete review on this topic [33], nanomedicines can employ multiple pathways 
for cellular entry. As clearly evidenced, the role of particle size, the shape, the material composition, 
surface chemistry and/or charge for utilization of a selected pathway(s) may strongly impact on the 
mechanism of internalization. Moreover, these parameters should effect also cell type accumulation 
and the overall fate of a nanomedicine relating to the effect of cell type on the processing of 
nanomedicines and the nanomaterial–cell interactions on the processes of endocytosis, as well as the 
resulting cellular responses [33]. In particular, their surface characteristic could strongly impact on cellular 
entry through definitive endocytic route(s) which could vary from caveolae- or clathrin-mediated pathways. 
Endocytosis of nanomedicine was deeply investigated, mainly in vitro, and with different outputs, 
leading to conflicting results [34]. The main issue is regarding the translatability of in vitro results to  
in vivo application and the reproducibility of the results. 
Few papers in reality report the effective in vivo endocytosis mechanism of NPs. As reported in a 
pivotal review on this topic: “developing assays to study the complex process of endocytosis of 
nanomedicines in vivo remain a key challenge for the future success of this field” [33]. 
One of the few papers which deeply investigated the endocytosis hypothesis is related to the exact 
mechanisms behind intracellular delivery of therapeutic compounds, endocytosis and pore formation 
which are involved [35]. The authors analyzed ultrasound and microbubble targeted delivery of 
therapeutic compounds and conclude that an evoked transient pore formation is happening (as 
demonstrated by the influx of calcium ions with the contribution of endocytosis being dependent on 
molecular size). This study is pivotal in the future direction of a real analysis of the molecular events 
which take place in the formation of endocytotic vesicle and it could be transferred to other examples, 
even in the case of neurons. 
Moreover, a deep debate is underway on the role and real value of in vitro experiments on 
endocytosis. Duncan and colleagues clearly demonstrated that the conditions of in vitro experiments 
(serum free, continuous incubation in cells and concentration of medium) are too far from in vivo 
environments [34]. Thus, a confirmation of any in vitro experiments with in vivo proofs must be 
obtained and the in vitro experiments should be planned accurately to mimic or at least to shorten the 
distance with in vivo condition. In fact, as reported “the substrate concentration, the kinetics of uptake, 
the time dependence of internalization and intracellular trafficking should be carefully considered 
when setting a protocol for in vitro studies in order to maximize relevance of the data obtained to the  
in vivo/clinical setting” [34]. 
Another big issue regards the healthy or diseased conditions of the target site on the uptake of 
nanomedicine: above the well-known debate on the role of inflamed or diseased BBB in the CNS 
targeting [36–39] the impact of the disease conditions in endocytosis routes is still unclear and needs a 
further clear assessment. In this view, the future direction of the research in this field is to verify that 
all in vitro cell models and in vivo disease models are properly validated with respect to their 
functional endocytosis and trafficking behavior. Thus, it becomes almost clear that the evaluation of 
possible failure or enhancement of the drug efficacy mediated by nanomedicine will not be linked  
only to pharmacological resistance or intrinsic causes of the drug, but also related to nanomedicine 
endocytosis, uptake and accumulation. 
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In this view, as reported previously, PLGA NPs endocytosis and uptake modified with g7 peptides 
were deeply investigated. This field of research represents a good example of in vitro and in vivo 
correlation with respect to experimental data. In fact, electron photomicrographs showed the ability  
only of g7-NPs to cross the BBB as evidenced by several endocytotic vesicles and macropinocytotic 
processes. In previous papers, we deeply analyzed the modality and mechanism of BBB crossing of  
g7-NPs in comparison with un-modified NPs: in vivo experiments on rodents clearly demonstrated that 
un-modified NPs (namely only made of the same polymer, PLGA, without any surface modification) 
were not able to be detected into the brain parenchyma, but only lying in the brain vessels [32]. 
Computational analysis on the conformation of the g7- and random-g7-NPs on the NPs surface was 
also performed. It showed a different conformation (linear versus globular), suggesting a different 
interaction with the BBB. 
Moreover, a deep study on the most important parameters (internal angles, distances, internal and 
planar/antiperiplanar conformation angles) was conducted on the g7-peptide, demonstrating that only 
g7-peptide does assume the helix-like conformation proposed by Pauling [40], i.e., the now called 
“Biousian Conformation”, already demonstrated for the native opioid peptide MMP-2200 [27]. 
The computational analysis showed the Biousian structure of the g7 peptide [25,27,41], while on the 
contrary, the random-g7 peptide showed a globular conformation, suggesting that this difference is 
pivotal to explain the BBB crossing and allows to hypothesize this as the mechanism of BBB crossing 
displayed by the g7-NPs. 
In order to hypothesize the mechanism of BBB crossing, it is important to consider that g7 derived 
from the native opioid peptide MMP-2200 and its ability to cross the BBB could be connected to  
the same mechanism used by the β-endorphines. These peptides cross the BBB adopting a helical 
amphipathic conformation in presence of BBB luminal wall lipid bilayers for which they have a high 
affinity [41]. It was demonstrated that these opioid peptides display a high level of amphipathicity with 
two conflicting solubility states (water-soluble random coil conformation and another at water-membrane 
phase boundaries); this conformation allows the helix insertion into the biological bilayers, correlated 
to a membrane-membrane interaction producing a membrane curvature [42]. 
g7-NPs could cross the BBB with the same modality, but with proper consideration of the “solid 
nature” of the carriers. Rigid protein, with intrinsic curvature and bound to the membrane surface, 
stabilizes the membrane curvature, which is mediated by the insertion of amphipathic moieties or 
helices of proteins between the polar head-groups of lipid molecules [43]. 
The same event is connected to g7-NPs, with a polymeric matrix structure (rigid) and decorated 
with an amphiphatic glycopeptides (g7) having helix-like conformation. Therefore, they could behave 
as a rigid high MW protein, producing the BBB membrane curvature. 
In previous papers [32], we clearly showed a real interaction of the g7-NPs to the surface of the 
BBB, confirming the involvement of the amphiphatic helices supposed by Polt et al. Moreover, after  
in vivo administration, we detected several ruffles, referable to macropinocytosis, were sometimes 
recognized when g7-NPs are near to the endothelial cells. It is well known that macropinocytosis, 
although not frequent at BBB level, is the major mechanism responsible for the BBB crossing by 
different pathogens [44–46] as well as by different nanoparticulate carriers. 
Taken together, these lines of evidence suggested that g7-NPs BBB crossing is owing to multiple 
pathways, mainly membrane–membrane interaction and macropinocytosis-like mechanisms. 
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Thus, these NPs cross the BBB by multiple pathways, such as endocytosis and macropinocytosis, 
and these pathways could play a pivotal role also in function of the progression of some CNS diseases. 
1.4. Trafficking inside the CNS 
The trafficking inside the CNS parenchyma and the preferential accumulation of NPs into neuronal 
cells is a poorly investigated issue in vitro and in vivo. Although only few examples could be found in 
the literature [47–49], if NP and BBB crossing is a well-known topic, it seems that the destiny of NPs 
after crossing the BBB is not known. On the contrary, the real fate of NPs is linked to their cell 
accumulation, intercellular trafficking, endocytosis processes and intracellular pathways, and therefore 
adequate understanding and investigation should be developed. 
Very recently, the cellular and intracellular destiny of g7-NPs after in vivo administration in mice 
(i.p.) was assessed [47,48]. In particular, as g7-NP distribution within the brain and their interaction 
with CNS cells need to be accurately assessed before they can be proposed for therapeutic use, in vivo 
administration of g7-NPs was demonstrated to lead to a region- and cell type-specific enrichment of 
NPs within the brain. g7-NPs can cross the BBB and target specific brain cell populations, suggesting 
that these NPs can be promising carriers for the treatment of neuropsychiatric and neurodegenerative 
diseases. Besides, as the fate of NPs once entered in the brain after crossing the BBB and taken up into 
neuronal cells is a neglected area of study, the possible mechanisms of a cell-to-cell transport of  
g7-NPs was investigated. In vivo experiments clearly showed that g7-NPs can be transported intra- and 
inter-cellularly within vesicles after vesicular internalization. Moreover, cell-to-cell transport is 
mediated by tunneling-nanotube (TNT)-like structures in cell lines and most interestingly in glial as 
well as neuronal cells in vitro. The transport is dependent on F-actin and can be increased by induction 
of TNT-like structures overexpressing M-Sec, a central factor and inducer of TNT formation. 
1.5. Rab GTPase in Vesicular Transport 
One group of proteins which are necessary for efficient intracellular membranous trafficking, 
including endocytosis, are Rab GTPases together with their effector proteins [50,51]. 
In their active states, Rab-GTP bound forms are distributed on the cytosolic face of specific 
membrane compartments where they regulate intracellular trafficking, including vesicle formation, 
motility, docking and fusion [52]. For example, Rab4, Rab5, and Rab11 are localized to early 
endosomes (EE) and serve different functions. In the endocytic pathway, both Rab4 and Rab5 proteins 
are associated with EE: Rab4 has been shown to be involved in the regulation of recycling from the EE 
and, in particular, Tfn receptor (TfR) recycling. Rab5, which is also on the plasma membrane, is 
important in the homotypic fusion between EE as well as in the transport to the early endosomal 
compartment (EEC) [53–55]. In addition, it seems to be also necessary for budding of vesicles from 
the plasma membrane and has been suggested to regulate transport beyond EEC [56]. An increase in 
the level of Rab5 stimulates endocytosis and expands the size of the EE but also accelerates recycling 
from the EE to the plasma membrane [54]; in contrast, overexpression of Rab4 increases the reflux of 
endocytic markers to the cell surface and induces the accumulation of endocytic tubes to a distinct 
recycling compartment [57]. Rab11, on the other hand, has been demonstrated to function in transport 
through the recycling compartment [58,59]. Two further examples of Rab proteins are localized to the 
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late endosomal compartment: Rab7 has been shown to control late endocytic trafficking while Rab9 
regulates transport from late endosomes to the trans Golgi network [60–62]. 
All types of Rab proteins are implicated in the regulation of distinct membrane traffic events in the cell. 
1.6. How to Set up NP Trafficking 
Another big issue is to start identifying a sort of protocol for screening and detecting the trafficking 
pathways of NPs. Therefore, we take advantage of the technology of NP labeling by means of polymer 
conjugation with dye [26,29,30,63–65]; with the use of Rhodamine conjugated PLGA, we thus aim to 
exploit confocal microscopy for clearly identifying, from a qualitative point of view, the cellular type/subtype 
in which NPs could be found. The set-up of this protocol is useful as the immunohistochemistry 
protocols are well established for cell markers (i.e., neurons, astrocyte, interneurons) but not with 
labeled NPs and their interaction with cells. In this paper, we therefore provide hints for this kind of 
protocols. Beside this technological aspect, proper investigations on cell type accumulation by g7-NPs 
after systemic administration in animal model will be given. 
Thus, in this paper, we tried to summarize some procedures and protocols which may help readers 
and researchers in performing experiments in vivo for detection of NPs (labeled) and for a clear 
assessment of the trafficking and accumulation of NPs in brain areas. 
Moreover, some new insights on the fate of g7-NPs will be given, especially regarding interneurons 
and clathrin–caveolin mediated processes. 
2. Case Analysis of g7-NPs 
As for materials and methods used, the major problem in standardization of results is the lack of 
homogeneity in experimental procedures. Therefore, in order to speed up the process of translatability 
of nanomedicine for brain targeting into clinical application, we refer to standard protocols (see 
Supplementary Information) which were applied in all the experiments we performed. In this way, we 
hope to help new studies in the organization of the workflow and especially to be in the same line and 
direction to achieve a good comparison of results. 
2.1. Nanoparticle Characterization and Confocal Protocols to Visualized NPs 
g7-NPs were characterized in their chemical–physical and morphological features, showing 
dimensions always in the range of 150 nm (30 nm as standard deviation) and featured by a regular 
surface as shown in previous paper by SEM analysis (data not shown) [47–49]. 
In order to set up the visualization of NPs, a plethora of experiments were conducted to optimize 
confocal features and performance. One of the first issues which should be taken into great 
consideration is linked to set up all the signals and the potency of the laser emission. These data will 
notably impact the signal detection, the amplitude of the signal and, moreover, the NP visualization. 
Besides these parameters, an important topic is also related to the possible overlapping of signals. 
In the case of g7-NPs labeled with Rhodamine, we set up a protocol for excitation/emission profiles 
clearly identifying NPs in comparison with other probes, featured by specific excitation/emission 
profiles. As reported in previous papers [64] after excitation at 514 nm, both PLGA and g7-PLGA 
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showed the same emission profile, i.e., a single emission peak close to 580 nm. Any mixture of PLGA 
and Rhod-PLGA did not show any overlap, showing absence of any interference in signals. 
2.2. Nanoparticle Accumulation in Endocytic Structures: Clathrin and Caveoline Positive Vesicles 
Clathrin mediated endocytosis represents the “classical route” of cellular entry, which is present and 
inherently active in all mammalian cells. For instance, it is responsible for uptake of essential nutrients 
like cholesterol carried into cells by low density lipoprotein (LDL) via the LDL receptor, or iron 
carried by Tfn via the TfR [33]. Recent studies reported that layered double hydroxide NP 
internalization in neurons is mediated by clathrin-dependent endocytosis and that NPs are targeted 
mainly to the clathrin endocytotic machinery [66,67]. As for layered double hydroxide NP [66], also 
g7-NP internalization is mediated by clathrin-dependent endocytosis in neurons [47,48]. To demonstrate 
this mechanism, we infused chlorpromazine hydrochloride or staurosporine, inhibitors of clathrin-dependent 
and caveolin dependent endocytosis, respectively, unilaterally within mouse hippocampus and, 15 min 
later, injected g7-NPs (300 ag/300 μL/mouse) peripherally. Infusion of the respective vehicles was 
performed into the contra-lateral hippocampus. As also occurred in vitro, we observed a marked 
decrease of g7-NP signal accumulation within hippocampal neurons in chlorpromazine-treated 
hippocampus but not in staurosporine-treated hippocampus. As demonstrated by confocal microscopy 
analysis g7-NPs strongly colocalized with clathrin related- but not with caveolin related-signal [47]. 
2.3. Determination of Positive g7-NP-Early Endosomes 
In the literature on cellular uptake of NPs, the discussion is restricted to clathrin-mediated and 
caveolae-mediated endocytosis without any consideration of transport inside cells mediated by EE.  
EE, in fact, represents the first major sorting station of the endosomal-lysosomal pathway and the site 
of internalization and initial processing of different biological mediators and proteins. In neurons, the 
endosomal-lysosomal pathway performs a multiplicity of integral functions including internalization of 
nutrients and neurotrophic factors, degradation and recycling of receptors and integration of signaling 
information to relevant intracellular pathways. 
In particular, endosomal Rab5 localized in EE, is known to play important roles in regulating the 
various stages of endosomal trafficking and fusion and its function in neuronal endocytosis has 
received much recent attention. To better elucidate g7-NP transport inside cells, we tested the 
colocalization of g7-NPs with the clathrin-related Rab5 and caveola-related EEA1 early endosome 
markers. In Figure 1, we reported an example of impressive colocalization of g7-NPs and Rab5 signals 
in hippocampal interneurons but only minimal co-localization with EEA1 signals in the same cells. 
This evidence, yet reported in previous papers [47,48], could be also connected to the accumulation 
of g7-NPs in presynaptic endosomes which are devoid of EEA1 [68]. Further experiments will be 
needed in order to better elucidate this aspect and to give new possible insights on the fate of NPs. 
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Figure 1. g7-NP uptake in vivo. (a–d) Confocal microscopy images of brain cryosections 
labelled with DAPI (blue), g7-NPs (red) and in green, rabbit anti-EEA1 (a,c) and rabbit 
anti Rab5 (b,d) from the hippocampal dentate gyrus of mice sacrificed 6 h after i.p. 
injection of g7-NPs. As shown in c, the dashed arrows indicate no overlapping between the 
red (g7-NP) and green (EEA1) signals; in d, arrows indicates a completely co-localization 
between red (g7-NP) and green signals (Rab5 ir) resulting in yellow labelling. Scale bar = 
50 μm (a–b); 10 μm (c–d). 
3. Commentary 
The fate and destiny of NPs is still unclear. Unfortunately, the researchers in this field are still 
anchored to a very conservative way of thinking and planning of the experiments, which is based on 
the assessment of the phenomena (i.e., presence or not inside the brain, pharmacological activity, etc.), 
but not the mechanisms. This approach was valid in past times, where nanomedicine was at its 
beginning and the knowledge on the mechanism of NP cell entry and BBB crossing was poor. 
Nowadays, major awareness of the role of endocytosis of nanomedicines, of their trafficking once 
they have crossed the BBB and possible accumulation and tropism in detailed areas or even cell types 
is present. Therefore, much attention to these topics must be devoted with proper in vivo protocols, 
clearly assessing the behavior of nanomedicines. 
In this view, we identified some pivotal points to be assessed in the evaluation of the potential of a 
nanocarrier for CNS drug delivery and targeting. 
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3.1. Technological Aspect 
Significant effort should be made in the pharmaceutical nanotechnology field; this would mean that  
major attention must be devoted to the choice: (i) of the starting material (biodegradable, FDA 
approved, natural or synthetic) allowing to a “safe and ready-to-use nanocarrier”; (ii) of the technology 
used for nanocarrier production (safe, ready for scale up, avoidance of organic solvents or 
methodology for removal) allowing to a “ready-to-be produced nanocarrier” ; (iii) of the protocols for 
chemico-physical characterization (use of scanning electron microscopy, atomic force microscopy, 
etc.) which strongly impact the real assessment of a “standardized nanocarrier”. 
3.2. In Vivo Experiments 
In vivo analysis should be performed on healthy and diseased animal models, as the potential of 
nanocarrier (independently from the ligand used for BBB crossing) is strongly affected by the state of 
the BBB (increased or decreased permeability, alteration of tight junctions, altered transcytotic 
processes) and of the CNS (inflamed area, preferential uptake by cells, etc.). 
3.3. In Vivo Sample Analysis 
Beside the aspect of animal models and experiments, the methodology used for assessing  
proof-of-concept and even therapeutic advantages of nanocarrier approaches should be standardized 
and optimized. Even if the radio-labeling is one of the few methods in order to give qualitative and 
quantitative results in terms of CNS accumulation of both loaded drugs and nanocarriers, the use of 
other methods (i.e., fluorescent labeled nanocarriers or drugs, pharmacological activity) needs a high 
level of procedural steps. If we will be able to find an optimized, transversal and globally applied 
protocol for NP detection (i.e., confocal analysis followed by immunohistochemistry or use of labeled 
polymers with stable linkage with dye, etc.), all the results obtained in the laboratories of different 
research groups will be comparable. 
By this new “wider” approach in nanomedicine investigation, the bench-to-bedside translatability of 
nanomedicines (from pre-clinical to clinical application) could be reached in shorter times as the 
validity of the experiments will be greatly improved. 
Acknowledgments 
Flavio Forni and Maria Angela Vandelli were supported by PRIN grant 2011 (No. 2010H834LS). 
The authors gratefully acknowledge the professional technical assistance of CIGS (University of 
Modena and Reggio Emilia) for assistance in confocal analysis. 
Author Contributions 
Antonietta Vilella and Giovanni Tosi carried out the in vivo studies and drafted the manuscript.  
Flavio Forni, Giovanni Tosi, Michele Zoli participated in the design of the study. Flavio Forni and 
Michele Zoli contributed to the coordination of the study. Giovanni Tosi, Barbara Ruozi, Daniela Belletti 
and Maria Angela Vandelli contributed to the preparation of modified NPs. All authors read and 
Pharmaceutics 2015, 7 85 
 
 
approved the final manuscript. Francesca Pederzoli, Marianna Galliani and Valentina Semeghini 
helped in the manuscript preparation and experiments. 
Conflicts of Interest 
The authors declare no conflict of interest. 
References 
1 Lo, E.H.; Singhal, A.B.; Torchilin, V.P.; Abbott, N.J. Drug delivery to damaged brain. Brain Res. 
Rev. 2001, 38, 140–148. 
2 Siegal, T.; Zylber-Katz, E. Strategies for increasing drug delivery to the brain: Focus on brain 
lymphoma. Clin. Pharmacokinet. 2002, 41, 171–186. 
3 Tosi, G.; Vergoni, A.V.; Ruozi, B.; Bondioli, L.; Badiali, L.; Rivasi, F.; Costantino, L.; Forni, F.; 
Vandelli, M.A. Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous 
system targeting: In vivo pharmacological evidence and biodistribution. J. Control. Release 2010, 
145, 49–57. 
4 Kreuter, J. Drug delivery to the central nervous system by polymeric nanoparticles: What do we 
know? Adv. Drug Deliv. Rev. 2014, 71, 2–14. 
5 Tosi, G.; Costantino, L.; Ruozi, B.; Forni, F.; Vandelli, M.A. Polymeric nanoparticles for the drug 
delivery to the central nervous system. Exp. Opin. Drug Deliv. 2008, 5, 155–174. 
6 Burkhart, A.; Azizi, M.; Thomsen, M.S.; Thomsen, L.B.; Moos, T. Accessing targeted nanoparticles 
to the brain: The vascular route. Curr. Med. Chem. 2014, 21, 4092–4099. 
7 van der Meel, R.; Vehmeijer, L.J.; Kok, R.J.; Storm, G.; van Gaal, E.V. Ligand-targeted 
particulate nanomedicines undergoing clinical evaluation: Current status. Adv. Drug Deliv. Rev. 
2013, 65, 1284–1298. 
8 Nagpal, K.; Singh, S.K.; Mishra, D.N. Nanoparticle mediated brain targeted delivery of gallic 
acid: In vivo behavioral and biochemical studies for improved antioxidant and antidepressant-like 
activity. Drug Deliv. 2012, 19, 378–391. 
9 Rip, J.; Chen, L.; Hartman, R.; van den Heuvel, A.; Reijerkerk, A.; van Kregten, J.; van der Boom, B.; 
Appeldoorn, C.; de Boer, M.; Maussang, D.; de Lange, E.C.; et al. Glutathione PEGylated 
liposomes: Pharmacokinetics and delivery of cargo across the blood-brain barrier in rats. J. Drug 
Target. 2014, 22, 460–467. 
10 Lindqvist, A.; Rip, J.; Gaillard, P.J.; Björkman, S.; Hammarlund-Udenaes, M. Enhanced brain 
delivery of the opioid peptide DAMGO in glutathione pegylated liposomes: A microdialysis 
study. Mol. Pharm. 2013, 10, 1533–1541. 
11 Gabathuler, R. Approaches to transport therapeutic drugs across the blood brain barrier to treat 
brain diseases. Neurobiol. Dis. 2010, 37, 48–57. 
12 Fiori, A.; Cardelli, P.; Negri, L.; Savi, M.R.; Strom, R.; Erspamer, V. Deltorphin transport across 
the blood-brain barrier. Proc. Natl. Acad. Sci. USA 1997, 94, 9469–9474. 
13 Roberts, R.L.; Fine, R.E.; Sandra, A. Receptor-mediated endocytosis of transferrin at the blood-
brain barrier. J. Cell Sci. 1993, 104, 521–532. 
  
Pharmaceutics 2015, 7 86 
 
 
14 Tabernero, A.; Velasco, A.; Granda, B.; Lavado, E.M.; Medina, J.M. Transcytosis of albumin in 
astrocytes activates the sterol regulatory element-binding protein-1, which promotes the synthesis 
of the neurotrophic factor oleic acid. J. Biol. Chem. 2002, 277, 4240–4246. 
15 Witt, K.A.; Huber, J.D.; Egleton, R.D.; Davis, T.P. Insulin enhancement of opioid peptide 
transport across the blood-brain barrier and assessment of analgesic effect. J. Pharmacol. Exp. Ther. 
2000, 295, 972–978. 
16 Pang, Z.; Lu, W.; Gao, H.; Hu, K.; Chen, J.; Zhang, C.; Gao, X.; Jiang, X.; Zhu, C. Preparation 
and brain delivery property of biodegradable polymersomes conjugated with OX26. J. Control. 
Release 2008, 128, 120–127. 
17 Shi, N.; Pardridge, W.M. Noninvasive gene targeting to the brain. Proc. Natl. Acad. Sci. USA 
2000, 97, 7567–7572. 
18 Shi, N.; Boado, R.J.; Pardridge, W.M. Receptor-mediated gene targeting to tissues in vivo 
following intravenous administration of pegylated immunoliposomes. Pharm. Res. 2001, 18, 
1091–1095. 
19 Huwyler, J.; Wu, D.; Pardridge, W.M. Brain drug delivery of small molecules using 
immunoliposomes. Proc. Natl. Acad. Sci. USA 1996, 93, 14164–14169. 
20 Zhang, Z.J.; Reynolds, G.P. A selective decrease in the relative density of parvalbumin-
immunoreactive neurons in the hippocampus in schizophrenia. Schizophr. Res. 2002, 55, 1–10. 
21 Zhang, Y.; Schlachetzki, F.; Pardridge, W.M. Global non-viral gene transfer to the primate brain 
following intravenous administration. Mol. Ther. 2003, 7, 11–18. 
22 Zhang, Y.; Schlachetzki, F.; Zhang, Y.F.; Boado, R.J.; Pardridge, W.M. Normalization of striatal 
tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with 
intravenous nonviral gene therapy and a brain-specific promoter. Hum. Gene Ther. 2004, 15, 339–350. 
23 Kreuter, J.; Shamenkov, D.; Petrov, V.; Ramge, P.; Cychutek, K.; Koch-Brandt, C.; Alyautdin, R. 
Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.  
J. Drug Target. 2002, 10, 317–325. 
24 Egleton, R.D.; Davis, T.P. Development of neuropeptide drugs that cross the blood-brain barrier. 
NeuroRx 2005, 2, 44–53. 
25 Lowery, J.J.; Yeomans, L.; Keyari, C.M.; Davis, P.; Porreca, F.; Knapp, B.I.; Bidlack, J.M.; 
Bilsky, E.J.; Polt, R. Glycosylation improves the central effects of DAMGO. Chem. Biol. Drug 
Design 2007, 69, 41–47. 
26 Costantino, L.; Gandolfi, F.; Tosi, G.; Rivasi, F.; Vandelli, M.A.; Forni, F. Peptide-derivatized 
biodegradable nanoparticles able to cross the blood-brain barrier. J. Control. Release 2005, 108, 
84–96. 
27 Polt, R.; Dhanasekaran, M.; Keyari, C.M. Glycosylated neuropeptides: A new vista for 
neuropsychopharmacology? Med. Res. Rev. 2005, 25, 557–585. 
28 Costantino, L.; Gandolfi, F.; Bossy-Nobs, L.; Tosi, G.; Gurny, R.; Rivasi, F.; Vandelli, M.A.; 
Forni, F. Nanoparticulate drug carriers based on hybrid poly(D,L-lactide-co-glycolide)-dendron 
structures. Biomaterials 2006, 27, 4635–4645. 
29 Tosi, G.; Rivasi, F.; Gandolfi, F.; Costantino, L.; Vandelli, M.A.; Forni, F. Conjugated poly(D,L-
lactide-co-glycolide) for the preparation of in vivo detectable nanoparticles. Biomaterials 2005, 
26, 4189–4195. 
Pharmaceutics 2015, 7 87 
 
 
30 Tosi, G.; Costantino, L.; Rivasi, F.; Ruozi, B.; Leo, E.; Vergoni, A.V.; Tacchi, R.; Bertolini, A.; 
Vandelli, M.A.; Forni, F. Targeting the central nervous system: In vivo experiments with peptide-
derivatized nanoparticles loaded with Loperamide and Rhodamine-123. J. Control. Release 2007, 
122, 1–9. 
31 Tosi, G.; Ruozi, B.; Belletti, D.; Vilella, A.; Zoli, M.; Vandelli, M.A.; Forni, F. Brain-targeted 
polymeric nanoparticles: In vivo evidence of different routes of administration in rodents. 
Nanomedicine 2013, 8, 1373–1383. 
32 Tosi, G.; Ruozi, B.; Belletti, D.; Vilella, A.; Zoli, M.; Vandelli, M.A.; Forni, F. Investigation on 
mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier. 
Nanomedicine 2011, 6, 423–436. 
33 Sahay, G.; Alakhova, D.Y.; Kabanov, A.V. Endocytosis of nanomedicines. J. Control. Release 
2010, 145, 182–195. 
34 Duncan, R.; Richardson, S.C. Endocytosis and intracellular trafficking as gateways for 
nanomedicine delivery: Opportunities and challenges. Mol. Pharm. 2012, 9, 2380–2402. 
35 Meijering, B.D.; Juffermans, L.J.; van Wamel, A.; Henning, R.H.; Zuhorn, I.S.; Emmer, M.; 
Versteilen, A.M.; Paulus, W.J.; van Gilst, W.H.; Kooiman, K.; et al. Ultrasound and microbubble-
targeted delivery of macromolecules is regulated by induction of endocytosis and pore formation. 
Circ. Res. 2009, 104, 679–687. 
36 Daneman, R. The blood-brain barrier in health and disease. Ann. Neurol. 2012, 72, 648–672. 
37 Lossinsky, A.S.; Shivers, R.R. Structural pathways for macromolecular and cellular transport 
across the blood-brain barrier during inflammatory conditions. Rev. Histol. Histopathol. 2004, 19, 
535–564. 
38 Hawkins, B.T.; Davis, T.P. The blood-brain barrier/neurovascular unit in health and disease. 
Pharmacol. Rev. 2005, 57, 173–185. 
39 Abbott, N.J.; Friedman, A. Overview and introduction: The blood-brain barrier in health and 
disease. Epilepsia 2012, 53 (Suppl 6), 1–6. 
40 Pauling, L.; Corey, R.B.; Branson, M.R. The structure of proteins: Two hydrogen-bonded helical 
configurations of the polypeptide chain. Proc. Natl. Acad. Sci. USA 1951, 37, 205–211. 
41 Dhanasekaran, M.; Palian, M.M.; Alves, I.; Yeomans, L.; Keyari, C.M.; Davis, P.; Bilsky, E.J.; 
Egleton, R.D.; Yamamura, H.I.; Jacobsen, N.E.; et al. Glycopeptides related to beta-endorphin 
adopt helical amphipathic conformations in the presence of lipid bilayers. J. Am. Chem. Soc. 
2005, 127, 5435–5448. 
42 McMahon, H.T.; Gallop, J. Membrane curvature and mechanisms of dynamic cell membrane 
remodeling. Nature 2005, 438, 590–596. 
43 Zimmemberg, G.; Kozlov, M.M. How proteins produce cellular membrane curvature. Nat. Rev. 
Mol. Cell. Biol. 2006, 7, 9–19. 
44 Nassif, X.; Bourdoulous, S.; Eugene, E.; Couraud, P.O. How do extracellular pathoges cross the 
blood brain barrier? Trends Microbiol. 2002, 10, 227–232. 
45 Coureuil, M.; Mikaty, G.; Miller, F.; Lécuyer, H.; Bernard, C.; Bourdoulous, S.; Duménil, G.; 
Mège, R.M.; Weksler, B.B.; Romero, I.A.; et al. Meningococcal type IV Pili recruit the polarity 
complex to cross the brain endothelium. Science 2009, 325, 83–87. 
Pharmaceutics 2015, 7 88 
 
 
46 Prasadaro, N.V.; Wass, C.A.; Weiser, J.N.; Stins, M.F.; Huang, S.H.; Kim, K.S. Outer membrane 
protein A-promoted of Escherichi coli contributes to invasiton of brain microvascular endothelial 
cell. Infect. Immun. 1996, 64, 146–153. 
47 Vilella, A.; Tosi, G.; Grabrucker, A.M.; Ruozi, B.; Belletti, D.; Vandelli, M.A.; Boeckers, T.M.; 
Forni, F.; Zoli, M. Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-
specific uptake and distribution. J. Control. Release 2014, 174, 195–201. 
48 Tosi, G.; Vilella, A.; Chhabra, R.; Schmeisser, M.J.; Boeckers, T.M.; Ruozi, B.; Vandelli, M.A.; 
Forni, F.; Zoli, M.; Grabrucker, A.M. Insight on the fate of CNS-targeted nanoparticles. Part II: 
Intercellular neuronal cell-to-cell transport. J. Control. Release 2014, 177, 96–107. 
49 Chhabra, R.; Grabrucker, A.M.; Veratti, P.; Belletti, D.; Boeckers, T.M.; Vandelli, M.A.;  
Forni, F.; Tosi, G.; Ruozi, B. Characterization of lysosome-destabilizing DOPE/PLGA 
nanoparticles designed for cytoplasmic drug release. Int. J. Pharm. 2014, 471, 349–357. 
50 Grant, B.D.; Donaldson, J.G. Pathways and mechanisms of endocytic recycling. Nat. Rev. Mol. 
Cell Biol. 2009, 10, 597–608. 
51 Zerial, M.; McBride, H. Rab proteins as membrane organizers. Nat. Rev. Mol. Cell Biol. 2001, 2, 
107–117. 
52 Van Der Sluijs, P.; Hull, M.; Zahraoui, A.; Tavitian, A.; Goud, B.; Mellman, I. The small GTP-
binding protein rab4 is associated with early endosomes. Proc. Natl. Acad. Sci. USA 1991, 88, 
6313–6317. 
53 Gorvel, J.P.; Chavrier, P.; Zerial, M.; Gruenberg, J. rab5 controls early endosome fusion in vitro. 
Cell 1991, 64, 915–925. 
54 Bucci, C.; Parton, R.G.; Mather, I.H.; Stunnenberg, H.; Simons, K.; Hoflack, B.; Zerial, M. The 
small GTPase rab5 functions as a regulatory factor in the early endocytic pathway. Cell 1992, 70, 
715–728. 
55 Stenmark, H.; Valencia, A.; Martinez, O.; Ullrich, O.; Goud, B.; Zerial, M. Distinct structural 
elements of rab5 define its functional specificity. EMBO J. 1994, 13, 575–583. 
56 McLauchlan, H.; Newell, J.; Morrice, N.; Osborne, A.; West, M.; Smythe, E. A novel role for 
Rab5-GDI in ligand sequestration into clathrin-coated pits. Curr. Biol. 1998, 8, 34–45. 
57 van der Sluijs, P.; Hull, M.; Webster, P.; Mâle, P.; Goud, B.; Mellman, I. The small GTP-binding 
protein rab4 controls an early sorting event on the endocytic pathway. Cell 1992, 70, 729–740. 
58 Ullrich, O.; Reinsch, S.; Urbe, S.; Zerial, M.; Parton, R.G. Rab11 regulates recycling through the 
pericentriolar recycling endosome. J. Cell Biol. 1996, 135, 913–924. 
59 Wilcke, M.; Johannes, L.; Galli, T.; Mayau, V.; Goud, B.; Salamero, J. Rab11 regulates the 
compartmentalization of early endosomes required for efficient transport from early endosomes to 
the trans-golgi network. J. Cell Biol. 2000, 151, 1207–1220. 
60 Feng, Y.; Press, B.; Wandinger-Ness, A.; Rab 7: An important regulator of late endocytic 
membrane traffic. J. Cell Biol. 1995, 131, 1435–1452. 
61 Vitelli, R.; Santillo, M.; Lattero, D.; Chiariello, M.; Bifulco, M.; Bruni, C.B.; Bucci, C. Role of 
the small GTPase Rab7 in the late endocytic pathway. J. Biol. Chem. 1997, 272, 4391–4397. 
62 Lombardi, D.; Soldati, T.; Riederer, M.A.; Goda, Y.; Zerial, M.; Pfeffer, S.R. Rab9 Functions in 
Transport between Late Endosomes and the Trans Golgi Network. EMBO J. 1993, 12, 677–682. 
Pharmaceutics 2015, 7 89 
 
 
63 Pascolo, L.; Bortot B.; Benseny-Cases, N.; Gianoncelli, A.; Tosi, G.; Ruozi, B.; Rizzardi, C.;  
De Martino, E.; Vandelli, M.A.; Severini, G.M. Detection of PLGA-based nanoparticles at a 
single-cell level by synchrotron radiation FTIR spectromicroscopy and correlation with X-ray 
fluorescence microscopy. Int. J. Nanomed. 2014, 9, 2791–2801. 
64 Tosi, G.; Bondioli, L.; Ruozi, B.; Badiali, L.; Severini, G.M.; Biffi, S.; De Vita, A.; Bortot, B.; 
Dolcetta, D.; Forni, F.; et al. NIR-labeled nanoparticles engineered for brain targeting: In vivo 
optical imaging application and fluorescent microscopy evidences. J. Neural Transm. 2011, 118, 
145–153. 
65 Bondioli, L.; Costantino, L.; Ballestrazzi, A.; Lucchesi, D.; Boraschi, D.; Pellati, F.; Benvenuti, S.; 
Tosi, G.; Vandelli, M.A. PLGA nanoparticles surface decorated with the sialic acid, N-acetylneuraminic 
acid. Biomaterials 2010, 31, 3395–3403. 
66 Wong, Y.Y.; Markham, K.; Xu, Z.P.; Chen, M.; Max Lu, G.Q.; Bartlett, P.F.; Cooper, H.M. 
Efficient delivery of siRNA to cortical neurons using layered double hydroxide nanoparticles. 
Biomaterials 2010, 31, 8770–8779. 
67 Harush-Frenkel, O.; Rozentur, E.; Benita, S.; Altschuler, Y.; Surface charge of nanoparticles 
determines their endocytic and transcytotic pathway in polarized MDCK cells. Biomacromolecules 
2008, 9, 435–443. 
68 Wilson, J.M.; de Hoop, M.; Zorzi, N.; Toh, B.H.; Dotti, C.G.; Parton, R.G. EEA1, a tethering 
protein of the early sorting endosome, shows a polarized distribution in hippocampal neurons, 
epithelial cells, and fibroblasts. Mol. Biol. Cell 2000, 11, 2657–2671. 
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/4.0/). 
